Abstract

Foxp3+ regulatory T (Treg) cells are a crucial immunosuppressive population of CD4+ T cells, yet the homeostatic processes and survival programs that maintain the Treg cell pool are poorly understood. Here we report that peripheral Treg cells markedly alter their proliferative and apoptotic rates to rapidly restore numerical deficit through an interleukin 2–dependent and costimulation-dependent process. By contrast, excess Treg cells are removed by attrition, dependent on the Bim-initiated Bak- and Bax-dependent intrinsic apoptotic pathway. The antiapoptotic proteins Bcl-xL and Bcl-2 were dispensable for survival of Treg cells, whereas Mcl-1 was critical for survival of Treg cells, and the loss of this antiapoptotic protein caused fatal autoimmunity. Together, these data define the active processes by which Treg cells maintain homeostasis via critical survival pathways.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445, 771–775 (2007).

  2. 2.

    et al. FOXP3+ regulatory T cells in the human immune system. Nat. Rev. Immunol. 10, 490–500 (2010).

  3. 3.

    et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6, 1142–1151 (2005).

  4. 4.

    et al. A major role for Bim in regulatory T cell homeostasis. J. Immunol. 186, 156–163 (2011).

  5. 5.

    et al. Opposing functions of the T cell receptor kinase ZAP-70 in immunity and tolerance differentially titrate in response to nucleotide substitutions. Immunity 27, 912–926 (2007).

  6. 6.

    et al. Foxp3+ regulatory T cells exert asymmetric control over murine helper responses by inducing Th2 cell apoptosis. Blood 118, 1845–1853 (2011).

  7. 7.

    et al. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun. Rev. 10, 744–755 (2011).

  8. 8.

    et al. Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation. J. Immunol. 181, 1835–1848 (2008).

  9. 9.

    et al. Homeostasis and function of regulatory T cells in aging. Curr. Opin. Immunol. 24, 482–487 (2012).

  10. 10.

    et al. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3, 135–142 (2002).

  11. 11.

    et al. Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood 120, 2417–2427 (2012).

  12. 12.

    & The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47–59 (2008).

  13. 13.

    The role of BH3-only proteins in the immune system. Nat. Rev. Immunol. 5, 189–200 (2005).

  14. 14.

    & BH3-Only proteins-essential initiators of apoptotic cell death. Cell 103, 839–842 (2000).

  15. 15.

    et al. A novel role of IL-2 in organ-specific autoimmune inflammation beyond regulatory T cell checkpoint: both IL-2 knockout and Fas mutation prolong lifespan of Scurfy mice but by different mechanisms. J. Immunol. 179, 8035–8041 (2007).

  16. 16.

    et al. Dual effects of TRAIL in suppression of autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells. J. Immunol. 185, 5259–5267 (2010).

  17. 17.

    et al. Defects in the Bcl-2-regulated apoptotic pathway lead to preferential increase of CD25 low Foxp3+ anergic CD4+ T cells. J. Immunol. 187, 1566–1577 (2011).

  18. 18.

    et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol. Cell 6, 1389–1399 (2000).

  19. 19.

    et al. Preferential control of induced regulatory T cell homeostasis via a Bim/Bcl-2 axis. Cell Death Dis. 3, e270 (2012).

  20. 20.

    et al. Selective impairment of CD4+CD25+Foxp3+ regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis. Int. Immunopharmacol. 11, 212–219 (2011).

  21. 21.

    et al. Defective cell death signalling along the Bcl-2 regulated apoptosis pathway compromises Treg cell development and limits their functionality in mice. J. Autoimmun. 38, 59–69 (2012).

  22. 22.

    et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 267, 1506–1510 (1995).

  23. 23.

    et al. Bclx regulates the survival of double-positive thymocytes. Proc. Natl. Acad. Sci. USA 92, 4763–4767 (1995).

  24. 24.

    et al. IL-10 produced by regulatory T cells contributes to their suppressor function by limiting inflammation at environmental interfaces. Immunity 28, 546–558 (2008).

  25. 25.

    et al. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development 127, 4949–4958 (2000).

  26. 26.

    et al. Mcl-1 is essential for germinal center formation and B cell memory. Science 330, 1095–1099 (2010).

  27. 27.

    et al. Fate mapping reveals separate origins of T cells and myeloid lineages in the thymus. Immunity 32, 426–436 (2010).

  28. 28.

    et al. The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages. J. Immunol. 181, 521–528 (2008).

  29. 29.

    et al. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426, 671–676 (2003).

  30. 30.

    et al. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 30, 3667–3683 (2011).

  31. 31.

    et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 286, 1735–1738 (1999).

  32. 32.

    et al. The BH3-only proteins Bim and Puma cooperate to impose deletional tolerance of organ-specific antigens. Immunity 37, 451–462 (2012).

  33. 33.

    et al. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311, 1924–1927 (2006).

  34. 34.

    et al. Intraclonal competition limits the fate determination of regulatory T cells in the thymus. Nat. Immunol. 10, 610–617 (2009).

  35. 35.

    & Thymic development and peripheral homeostasis of regulatory T cells. Curr. Opin. Immunol. 19, 176–185 (2007).

  36. 36.

    et al. Foxp3 is pro-apoptotic and lethal to developing regulatory T cells unless counterbalanced by cytokine survival signals. Immunity (in the press) (2013).

  37. 37.

    CD4+ CD25+ Treg: divide and rule? Immunology 111, 129–137 (2004).

  38. 38.

    et al. Partial depletion of CD69low-expressing natural regulatory T cells with the anti-CD25 monoclonal antibody PC61. Scand. J. Immunol. 65, 63–69 (2007).

  39. 39.

    et al. Dendritic cells support homeostatic expansion of Foxp3+ regulatory T cells in Foxp3.LuciDTR mice. J. Immunol. 184, 1810–1820 (2010).

  40. 40.

    et al. Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nat. Immunol. 14, 262–270 (2013).

  41. 41.

    B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J. Immunol. 183, 3561–3567 (2009).

  42. 42.

    & IL-7 signaling and CD127 receptor regulation in the control of T cell homeostasis. Semin. Immunol. 24, 209–217 (2012).

  43. 43.

    et al. Autologous regulation of naive T cell homeostasis within the T cell compartment. J. Immunol. 166, 2460–2468 (2001).

  44. 44.

    et al. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J. Exp. Med. 198, 937–945 (2003).

  45. 45.

    et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322, 271–275 (2008).

  46. 46.

    et al. Dicer-dependent microRNA pathway safeguards regulatory T cell function. J. Exp. Med. 205, 1993–2004 (2008).

  47. 47.

    et al. Essential role of BAX,BAK in B cell homeostasis and prevention of autoimmune disease. Proc. Natl. Acad. Sci. USA 102, 11272–11277 (2005).

  48. 48.

    et al. IL-15 fosters Treg accrual in aging in the face of declining IL-2 levels. Front. Immunol. (in the press).

  49. 49.

    et al. Notch-RBP-J signaling controls the homeostasis of CD8- dendritic cells in the spleen. J. Exp. Med. 204, 1653–1664 (2007).

  50. 50.

    et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22, 329–341 (2005).

  51. 51.

    et al. Differentiation of regulatory Foxp3+ T cells in the thymic cortex. Proc. Natl. Acad. Sci. USA 105, 11903–11908 (2008).

  52. 52.

    et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 68, 869–877 (1992).

  53. 53.

    et al. Continued RAG expression in late stages of B cell development and no apparent re-induction after immunization. Nature 400, 682–687 (1999).

  54. 54.

    et al. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev. Biol. 1, 4 (2001).

  55. 55.

    et al. A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat. Methods 2, 419–426 (2005).

  56. 56.

    et al. Rapid generation of inducible mouse mutants. Nucleic Acids Res. 31, e12 (2003).

  57. 57.

    et al. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8, 191–197 (2007).

  58. 58.

    et al. IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25. Proc. Natl. Acad. Sci. USA 107, 2171–2176 (2010).

  59. 59.

    et al. CASVM: web server for SVM-based prediction of caspase substrates cleavage sites. Bioinformatics 23, 3241–3243 (2007).

Download references

Acknowledgements

We thank P. Fink (University of Washington, Seattle) for providing Rag2–GFP-Tg mice backcrossed to the B6 background, L. Hennighausen (US National Institutes of Health) for providing Bcl2l1fx mice, A. Rudensky (Memorial Sloan-Kettering Cancer Center) for providing Foxp3GFP, Foxp3Cre, Foxp3Thy1.1 and Foxp3DTR mice, G. Kelly and S. Grabow (Walter and Eliza Hall Institute of Medical Research) for CreERT2Mcl1fl and CreERT2Bcl2l1flox mice and Bcl2−/− fetal liver samples, F. Kupresanin, G. Siciliano, G.-F. Dabrowski, K. Humphreys and E. Lanera (Walter and Eliza Hall Institute of Medical Research) for technical assistance, S. Korsmeyer (Harvard Medical School) for BaxflBak1/ mice, and A. Kallies for critical feedback on the manuscript. This work was supported by grants from the VIB, Marie Curie (TREG to A.L.), European Research Council (IMMUNO to A.L.), Interuniversity Attraction Poles (VII/39 to A.L and P.M.), QSIS (to A.A.F.) and the Australian National Health and Medical Research Council (CDF-1 #637353 to D.H.D.G.). W.P. is funded by Agentschap voor Innovatie door Wetenschap en Technologie. B.C., S.M.S. and S.H.-B. are funded by the Fonds Wetenschappelijk Onderzoek. This work was made possible through Victorian State Government Operational Infrastructure Support and the Australian Government National Health and Medical Research Council Independent Research Institutes Infrastructure Support Scheme.

Author information

Author notes

    • Daniel H D Gray
    •  & Adrian Liston

    These authors contributed equally to this work.

Affiliations

  1. Autoimmune Genetics Laboratory, VIB, Leuven, Belgium.

    • Wim Pierson
    • , Bénédicte Cauwe
    • , Susan M Schlenner
    • , Dean Franckaert
    • , Stephanie Humblet-Baron
    • , Susann Schönefeldt
    • , James Dooley
    •  & Adrian Liston
  2. Department of Microbiology and Immunology, University of Leuven, Leuven, Belgium.

    • Wim Pierson
    • , Bénédicte Cauwe
    • , Susan M Schlenner
    • , Dean Franckaert
    • , Stephanie Humblet-Baron
    • , Susann Schönefeldt
    • , James Dooley
    •  & Adrian Liston
  3. The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.

    • Antonia Policheni
    • , Marco J Herold
    • , Andreas Strasser
    • , Philippe Bouillet
    •  & Daniel H D Gray
  4. Department of Medical Biology, University of Melbourne, Melbourne, Australia.

    • Antonia Policheni
    • , Marco J Herold
    • , Andreas Strasser
    • , Philippe Bouillet
    •  & Daniel H D Gray
  5. Unité de Biologie des Populations Lymphocytaires, Department of Immunology, Institut Pasteur, Paris, France.

    • Julien Berges
    •  & Antonio A Freitas
  6. Centre National de la Recherché Scientifique, Unité de Recherche Associée 1961, Paris, France.

    • Julien Berges
    •  & Antonio A Freitas
  7. Division of Immunobiology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

    • David Hildeman
  8. Children's Hospital Medical Center, Cincinnati, Ohio, USA.

    • David Hildeman
  9. Section of Molecular Biology, Division of Biological Sciences, University of California–San Diego, La Jolla, California, USA.

    • Li-Fan Lu
  10. Laboratory of Immunobiology, Rega Institute, University of Leuven, Leuven, Belgium.

    • Patrick Matthys
  11. Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

    • Rita J Luther
    •  & Casey T Weaver

Authors

  1. Search for Wim Pierson in:

  2. Search for Bénédicte Cauwe in:

  3. Search for Antonia Policheni in:

  4. Search for Susan M Schlenner in:

  5. Search for Dean Franckaert in:

  6. Search for Julien Berges in:

  7. Search for Stephanie Humblet-Baron in:

  8. Search for Susann Schönefeldt in:

  9. Search for Marco J Herold in:

  10. Search for David Hildeman in:

  11. Search for Andreas Strasser in:

  12. Search for Philippe Bouillet in:

  13. Search for Li-Fan Lu in:

  14. Search for Patrick Matthys in:

  15. Search for Antonio A Freitas in:

  16. Search for Rita J Luther in:

  17. Search for Casey T Weaver in:

  18. Search for James Dooley in:

  19. Search for Daniel H D Gray in:

  20. Search for Adrian Liston in:

Contributions

W.P., B.C., A.P., S.M.S., J.B., M.J.H., S.S., D.F., S.H.-B., L.-F.L. and J.D. performed the experiments. D.H., A.S., P.B., R.J.L. and C.T.W. provided key reagents. S.M.S., A.A.F., P.M., J.D., D.H.D.G. and A.L. designed the study. W.P., D.H.D.G. and A.L. wrote the manuscript. All authors read and approved the manuscript.

Competing interests

The spouse of A.L. is an employee of UCB Pharma.

Corresponding authors

Correspondence to Daniel H D Gray or Adrian Liston.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–8

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ni.2649

Further reading